Nausea

MASCC/ESMO Update Guidelines for CINV Prophylaxis

MASCC/ESMO Update Guidelines for CINV Prophylaxis

By

The Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO) have updated their recommendations for the prevention of nausea and vomiting following multiple-day chemotherapy.

Rolapitant Improves CINV Prevention in Patients With GI Cancers

Rolapitant Improves CINV Prevention in Patients With GI Cancers

By

Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone significantly improved the prevention of CINV in patients with GI and CRC cancers receiving highly or moderately emetogenic chemotherapy.

Rolapitant Improves QoL in Patients Receiving HEC or MEC

Rolapitant Improves QoL in Patients Receiving HEC or MEC

By

Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone improved quality of life.

Premedication With Antiemetic Improves Length of Stay and Readmissions for a Liver Cancer Procedure

By

Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.

Dronabinol for Chemotherapy-induced Nausea and Vomiting Unresponsive to Antiemetics

Dronabinol for Chemotherapy-induced Nausea and Vomiting Unresponsive to Antiemetics

[Cancer Management and Research] This review focuses on dronabinol and its role in the treatment of chemotherapy-induced nausea and vomiting (CINV).

Helping Families Cope With Cancer-related Anorexia and Cachexia

Helping Families Cope With Cancer-related Anorexia and Cachexia

By

Loss of appetite and not eating are difficult aspects of cancer for patients' loved ones to understand. Continued and diligent nurse education can help both patients and families cope with this disturbing effect.

Personalized Antinausea Regimens More Effective in Cancer Patients Receiving Emetogenic Chemotherapy

By

A personalized approach to treating nausea and vomiting, the most expected side effects of chemotherapy, is far more effective than the existing one-size-fits-all guidelines.

Ramosetron vs. Ondansetron for Prevention of CINV Assessed

Ramosetron vs. Ondansetron for Prevention of CINV Assessed

By

Ramosetron plus dexamethasone and aprepitant is as effective and tolerable as ondansetron.

Cannabis Not Advantageous for Prevention of Post-op Nausea

Cannabis Not Advantageous for Prevention of Post-op Nausea

Clinically relevant psychotropic side effects plus ineffectiveness halted study of cannabis use to prevent postoperative nausea.

Adding rolapitant improves prevention of chemo-induced nausea, vomiting

Adding rolapitant improves prevention of chemo-induced nausea, vomiting

Rolapitant demonstrates superiority over active control for the prevention of chemotherapy-induced nausea and vomiting.

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting

[Cancer Management and Research] This research examines the incidence of chemotherapy-induced nausea/vomiting (CINV) and treatment delay among patients receiving palonosetron versus other 5-hydroxytryptamine receptor antagonist (5-HT3 RA) antiemetics.

Study identifies perception gap in incidence, impact of CINV/RINV

Study identifies perception gap in incidence, impact of CINV/RINV

There is a perpetual gap between healthcare professionals and patient perceptions of incidence and impact on patients' daily life of CINV/RINV.

Transdermal Granisetron May Be Appropriate for CINV Prevention in Lung Cancer

Transdermal Granisetron May Be Appropriate for CINV Prevention in Lung Cancer

By

Granisetron transdermal system (GTS) may be appropriate for prevention of chemotherapy-induced nausea and vomiting (CINV) in lung cancer.

Comparison of medications for managing nausea and vomiting

Comparison of medications for managing nausea and vomiting

By

Is a comparison guide for common medications used for side-effect management, such as constipation, nausea, anxiety, etc. that includes a cost comparison available?

FDA approves Akynzeo to prevent chemotherapy-induced nausea and vomiting

FDA approves Akynzeo to prevent chemotherapy-induced nausea and vomiting

Akynzeo approved for the treatment chemotherapy-induced nausea and vomiting (CINV) in patients with cancer.

Rolapitant reduces nausea and vomiting in phase III trial

By

For patients receiving cisplatin-based chemotherapy, rolapitant can reduce nausea-related side effects.

Management of chemotherapy-induced nausea and vomiting (CINV)

Management of chemotherapy-induced nausea and vomiting (CINV)

By

Could a medication indicated for nausea and vomiting in pregnancy resolve the same symptoms in patients undergoing chemotherapy?

Ginger extract improves chemotherapy-induced nausea, vomiting

Ginger extract improves chemotherapy-induced nausea, vomiting

By

A ginger extract, 6-gingerol, improves chemotherapy-induced nausea and vomiting (CINV), according to findings from a phase 2 randomized trial presented at the 2014 Annual ASCO Meeting.

Patients' symptom concerns before anticancer treatment predict symptom burdens

Patients' symptom concerns before anticancer treatment predict symptom burdens

By

Patients who express pretreatment concern about treatment symptoms such as nausea and memory problems tend to suffer higher symptom burdens during and after anticancer treatment, suggests research.

Advocating for treatment of anticipatory reactions

Advocating for treatment of anticipatory reactions

By

What can nurses do to advocate for the use of medications such as lorezepam (Ativan) for anticipatory nausea when the physician is reluctant to prescribe antianxiety or sleep medications?

Study drug makes marrow transplant possible in relapsed leukemia

The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.

Ibrutinib appears safe, effective against chronic lymphocytic leukemia

Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.

FDA pulls 32-mg IV ondansetron dose from market

The 32-mg, single IV dose of the anti-nausea drug Zofran (ondansetron) will no longer be sold due to the potential for serious cardiac risks.

Tips for Managing Nausea and Increasing Appetite During Cancer Treatment

Tips for Managing Nausea and Increasing Appetite During Cancer Treatment

This fact sheet contains tips for patients dealing with nausea and loss of appetite resulting from cancer treatment.

Lidiando con las Nauseas y Vomitos Inducidos por la Quimioterapia (Coping with Chemotherapy-Induced Nausea and Vomiting)

Lidiando con las Nauseas y Vomitos Inducidos por la Quimioterapia (Coping with Chemotherapy-Induced Nausea and Vomiting)

This fact sheet is written in Spanish to help patients cope with nausea and vomiting associated with chemotherapy.

New Drug Approved for Chemo-Related Severe Neutropenia

New Drug Approved for Chemo-Related Severe Neutropenia

The FDA has approved tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have severe neutropenia.

Grapefruit juice harnesses power of sirolimus

Consuming 8 ounces of grapefruit juice increases sirolimus levels by 350%, allowing persons with cancer to take less toxic doses of the drug.

Prolonged Dexamethasone Cuts Delayed Nausea After Chemo

Prolonged Dexamethasone Cuts Delayed Nausea After Chemo

Adding dexamethasone to prochlorperazine on days two and three reduces delayed nausea after chemotherapy.

FDA Update - July/August 2012

News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik

Dabrafenib shows promising results in BRAF-mutated melanoma

The drug dabrafenib significantly improved progression-free survival in persons with BRAF-mutation-positive metastatic melanoma in a phase 3 trial.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs